ADCX-020 for advanced or metastatic cancers
Part of Cancer clinical trials.
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has spread or cannot be removed, and it has not responded to standard treatments.
- You have at least one tumor that can be measured on scans.
- You are willing to provide a sample of your tumor tissue.
- You have recovered from side effects of previous cancer treatments.
- You have a good performance status (able to do daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MDX2004 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if the drug is safe and if it helps shrink tumors.
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Advanced Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.